Compare PCTY & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCTY | TECH |
|---|---|---|
| Founded | 1997 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 11.2B |
| IPO Year | 2014 | 1995 |
| Metric | PCTY | TECH |
|---|---|---|
| Price | $145.50 | $72.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 11 |
| Target Price | ★ $176.59 | $71.82 |
| AVG Volume (30 Days) | 798.5K | ★ 3.3M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.62% |
| EPS Growth | ★ 22.39 | N/A |
| EPS | ★ 4.92 | 0.81 |
| Revenue | ★ $1,771,326,000.00 | $1,219,635,000.00 |
| Revenue This Year | $11.52 | $2.49 |
| Revenue Next Year | $7.98 | $6.40 |
| P/E Ratio | ★ $30.14 | $89.38 |
| Revenue Growth | ★ 11.04 | 5.23 |
| 52 Week Low | $92.99 | $43.20 |
| 52 Week High | $182.83 | $72.43 |
| Indicator | PCTY | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 59.57 | 72.95 |
| Support Level | $140.42 | $71.89 |
| Resistance Level | $152.65 | N/A |
| Average True Range (ATR) | 6.61 | 0.27 |
| MACD | -0.35 | -0.39 |
| Stochastic Oscillator | 54.65 | 76.71 |
Paylocity is a cloud-based human capital management provider offering payroll, compliance, and human resources management solutions. With the addition of expense and IT management modules, Paylocity unifies back-office operations spanning HR, finance, and IT on a single platform and bills customers on a subscription basis. The firm's customer base skews toward the midmarket and is primarily based in the US. As of fiscal 2026, Paylocity has nearly 44,400 customers.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.